Literature DB >> 15223433

Clinicopathologic features of peripheral squamous cell carcinoma of the lung.

Hiroyuki Sakurai1, Hisao Asamura, Shun-ichi Watanabe, Kenji Suzuki, Ryosuke Tsuchiya.   

Abstract

BACKGROUND: The clinicopathologic features are still unknown in peripheral squamous cell carcinoma of the lung, unlike centrally located carcinomas. In this retrospective study, we investigated the clinicopathologic characteristics of patients with peripheral squamous cell carcinomas.
METHODS: Of 1,381 primary lung carcinomas surgically resected at the National Cancer Center Hospital, Tokyo, from 1995 through 2001, 70 (5.1%) peripheral squamous cell carcinomas of 3.0 cm or less in diameter were studied retrospectively in terms of clinicopathologic characteristics such as age, sex, past history, smoking, tumor size, mode of operation, extent of lymph node dissection, pathologic lymph node status, mode of recurrence, and cause of death.
RESULTS: These patients ranged in age from 49 to 82 years, with a mean age of 69.2 years. Thirty-nine patients (56%) were at increased risk preoperatively. The incidence of lymph node metastasis was 25%, and larger tumors tended to be associated with a higher prevalence, although this difference was not significant (p = 0.12). None of the patients with N2 disease had skipping metastasis. Recurrence was observed in 13 patients (19%). There was no significant correlation between recurrence and the extent of lymphadenectomy or the mode of operation. The 5-year overall and disease-specific survival rates were 73.4% and 85.9%, respectively. The cause of death was recurrence in 53% and other disease in 47%.
CONCLUSIONS: We propose that mediastinal hilar lymphadenectomy should be routinely conducted as a curative operation for low-risk patients with small peripheral squamous cell carcinoma. We further propose that for patients who may have difficulty tolerating this procedure, pathologic examination of intraoperative frozen sections from the hilar node could be useful for planning a surgical strategy.

Entities:  

Mesh:

Year:  2004        PMID: 15223433     DOI: 10.1016/j.athoracsur.2004.01.029

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  20 in total

1.  Squamous cell carcinoma of the lung: pattern of epidermal growth factor receptor mutation distribution in different populations: a summary.

Authors:  Viroj Wiwanitkit
Journal:  Lung       Date:  2006 Sep-Oct       Impact factor: 2.584

2.  Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations.

Authors:  Youngkyu Moon; Kyo Young Lee; Sook Whan Sung; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  Spontaneous primary squamous cell carcinoma of the lung in a rhesus macaque (Macaca mulatta).

Authors:  Sherrie M Jean; Pablo R Morales; Katherine Paul; AnaPatricia Garcia
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-05       Impact factor: 1.232

4.  Clinicopathological features of small-sized peripheral squamous cell lung cancer.

Authors:  Takayuki Kosaka; Kimihiro Shimizu; Seshiru Nakazawa; Misaki Iijima; Yoichi Ohtaki; Yoko Azuma; Kai Obayashi; Toshiteru Nagashima; Toshiki Yajima; Akira Mogi; Hiroyuki Kuwano; Ken Shirabe
Journal:  Mol Clin Oncol       Date:  2019-11-18

5.  Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Authors:  Natasha Rekhtman; Paul K Paik; Maria E Arcila; Laura J Tafe; Geoffrey R Oxnard; Andre L Moreira; William D Travis; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

Review 6.  State of the art in surgery for early stage NSCLC-does the number of resected lymph nodes matter?

Authors:  Laura Romero Vielva; Manuel Wong Jaen; José A Maestre Alcácer; Mecedes Canela Cardona
Journal:  Transl Lung Cancer Res       Date:  2014-04

7.  Choice of the surgical approach for patients with stage I lung squamous cell carcinoma ≤3 cm.

Authors:  Chunji Chen; Yiyang Wang; Xufeng Pan; Shijie Fu; Yubo Shi; Jun Yang; Rui Wang
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

8.  Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients.

Authors:  Hideaki Yashima; Kimihiro Shimizu; Takuya Araki; Tohru Aomori; Yoichi Ohtaki; Toshiteru Nagashima; Yasuaki Enokida; Jun Atsumi; Tomonori Nakamura; Izumi Takeyoshi; Koujirou Yamamoto
Journal:  Mol Clin Oncol       Date:  2014-06-03

9.  Glycemic Index, Glycemic Load, and Lung Cancer Risk in Non-Hispanic Whites.

Authors:  Stephanie C Melkonian; Carrie R Daniel; Yuanqing Ye; Jeanne A Pierzynski; Jack A Roth; Xifeng Wu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-03       Impact factor: 4.254

10.  Comprehensive investigation of clinicopathologic features, oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma.

Authors:  Yang Zhang; Difan Zheng; Yuan Li; Yunjian Pan; Yihua Sun; Haiquan Chen
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.